How These Generic Drugs Stocks are Faring? -- Neurocrine Biosciences, Evoke Pharma, SCYNEXIS, and Eagle Pharma

Friday, February 3, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, February 3, 2017 /PRNewswire/ --

On Thursday, February 02, 2017, the NASDAQ

Composite and the Dow Jones Industrial Average edged lower, while the S&P 500 finished on a bullish note at the closing bell. Yesterday's trading session saw a mixed performance in the US markets as four sectors closed in green, four sectors finished
in red, and one sector ended flat for the day. Taking into consideration yesterday's market sentiment, assessed the following Drugs - Generic equities this morning: Neurocrine Biosciences Inc. (NASDAQ: NBIX), Evoke Pharma Inc. (NASDAQ: EVOK), SCYNEXIS Inc. (NASDAQ: SCYX), and Eagle Pharmaceuticals Inc. (NASDAQ: EGRX). Download the free research reports on these stocks today:

Neurocrine Biosciences  

San Diego, California headquartered Neurocrine Biosciences Inc.'s stock finished Thursday's session 0.94% lower at $42.15 with a total volume of 1.03 million shares traded. Over the last one month and the previous one year, Neurocrine Biosciences' shares have gained 9.03% and 6.82%, respectively. The Company's shares are trading below its 50-day and 200-day moving averages by 1.22% and 9.48%, respectively. Shares of Neurocrine Biosciences, which discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the US, have a Relative Strength Index (RSI) of 53.16.

On January 27th, 2017, research firm Oppenheimer upgraded the Company's stock rating from 'Perform' to 'Outperform'. See our free and comprehensive research report on NBIX at:

Evoke Pharma  

On Thursday, shares in Solana Beach, California headquartered Evoke Pharma Inc. ended the session 3.20% lower at $2.72 with a total volume of 214,162 shares traded. Evoke Pharma's shares have rallied 31.40% in the last one month and 70.00% in the previous three months. The stock is trading 31.19% above its 50-day moving average. Moreover, shares of the Company, which primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases, have an RSI of 65.52.

On January 30th, 2017, research firm Laidlaw upgraded the Company's stock rating from 'Neutral' to 'Buy', with a target price of $8 per share. EVOK free research report PDF is just a click away at:


On Thursday, shares in Jersey City, New Jersey headquartered SCYNEXIS Inc. recorded a trading volume of 1.08 million shares, which was higher than their three months average volume of 361,530 shares. The stock ended the day 2.01% lower at $2.92. The Company is trading below its 50-day and 200-day moving averages by 14.75% and 9.41%, respectively. Furthermore, shares of SCYNEXIS, which develops and commercializes novel anti-infectives to address unmet therapeutic needs, have an RSI of 33.81. Sign up for your complimentary report on SCYX at:

Eagle Pharma  

Woodcliff Lake, New Jersey headquartered Eagle Pharmaceuticals Inc.'s stock edged 0.50% higher, to close the day at $68.69. The stock recorded a trading volume of 236,301 shares. Eagle Pharma's shares have gained 20.00% in the previous three months and 9.45% in the past one year. The Company's shares are trading 16.53% above its 200-day moving average. Shares of the Company, which focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the US, are trading at a PE ratio of 44.66. Additionally, the stock has an RSI of 46.96.

On January 09th, 2017, research firm Mizuho downgraded the Company's stock rating from 'Neutral' to 'Underperform' while revising its previous target price from $78 a share to $64 a share. Register for free on and download the latest research report on EGRX at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store